LEO Pharma applies to EMA to expand Anzupgo use to adolescents

The expansion is targeted at individuals for whom topical corticosteroids are not sufficient or appropriate. The European regulator has accepted the application for review.

The submission is based on outcomes from the Phase III trial, DELTA Teen, which evaluated the safety and efficacy of Anzupgo 20mg/g cream applied twice daily against a cream vehicle in this patient group.

Detailed findings from the trial were shared as a late-breaking presentation at the European Academy of Dermatology and Venereology 2025, held in Paris, France.

Research indicates that CHE in adolescents can affect more than just the skin, with significant impacts on quality of life, psychosocial health and academic performance.

The therapy is approved for use in adults with moderate to severe CHE for whom topical corticosteroids are not appropriate or sufficient in the EU, Switzerland, the US, and the UK.

LEO Pharma obtained exclusive development and commercialisation rights in 2014 for the topical use of delgocitinib in dermatological indications globally, except in Japan where Shionogi holds the rights.

LEO Pharma Development executive vice-president Sophie Lamle stated: “With the submission of our label expansion application for Anzupgo, LEO Pharma is reinforcing our commitment aiming at improving the lives of patients with skin diseases.

The post LEO Pharma applies to EMA to expand Anzupgo use to adolescents appeared first on Pharmaceutical Business review.